Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2022

Efficacité et innocuité de l'Ixekizumab chez les patients atteints de rhumatisme psoriasique actif avec ou sans traitement antirhumatismal conventionnel concomitant : Résultats à 3 ans de SPIRIT-P1 et SPIRIT-P2

Clin Rheumatol. 2022 doi: 10.1007/s10067-022-06218-8

Coates LC,

Mease P,

Kronbergs A,

Helt C,

Sandoval D,

Park SY,

Combe B,

Nash P,

Deodhar A

In this investigation ixekizumab showed sustained efficacy in PsA therapy for up to three years in both monotherapy and combination with MTX or a csDMARD. Here, investigators set out to evaluate the three-year efficacy and safety of ixekizumab with and without csDMARD use in patients with active PsA.

Keywords:

June 2020

Interruption Temporaire du Baricitinib : Caractérisation des Interruptions et Effet sur les Résultats Cliniques chez les Patients Atteints de Polyarthrite Rhumatoïde

Arth Res Ther 2020;22:115 doi.org/10.1186/s13075-020-02199-8

Emery P,

Helt C,

This study aimed to characterize temporary interruptions of baricitinib and describe their impact on efficacy and safety. Brief interruptions during phase 3 baricitinib trials were associated with minor increases in symptoms which were resolved following treatment. In life-long, chronic conditions such as RA, interruption of therapy is common for various reasons, such as side effects, non-compliance, or because a patient requires surgery. Concerns have been raised that these treatment breaks cou...

Keywords:

November 2018

Innocuité et efficacité du Baricitinib chez les patients recevant des médicaments antirhumatismaux synthétiques conventionnels modifiant la maladie ou des corticostéroïdes

Rheumatol Ther 2018 Dec;5(2):525-536. DOI 10.1007/s40744-018-0128-0

van Vollenhoven R,

Helt C,

Arora V,

Zhong J,

Correia AP,

de la Torre I,

Muram D

Baricitinib (BARI) in combination with MTX and concomitant csDMARDs was shown to be efficacious, regardless of corticosteroid use in RA patients. MTX is prescribed to most RA patients but concomitant csDMARDs and/or corticosteroids can be added. This study assessed the efficacy and safety of BARI in two arms; with/without corticosteroids and; with MTX only/MTX plus csDMARD/csDMARDs only. Baseline characteristics and adverse reactions were also compared. Data were pooled from two phase 3 studies ...